A three panel study, to determine if MK-8266 given as a single dose is sufficiently safe and
well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of
subjects with mild to moderate hypertension. The primary hypotheses for the study are that
MK-8266 given as single doses is sufficiently safe and well tolerated to permit continued
clinical investigation in healthy young male volunteers and male participants with
mild-to-moderate hypertension and that in males with mild to moderate hypertension, at a
single oral dose of MK-8266 that is sufficiently safe and well-tolerated, postdose mean
time-weighted average across 24 hours of aortic augmentation index (TWA0-12hrs AIx) is
reduced compared to placebo. A mean decrease of ≥ 5 percentage points is considered
clinically meaningful.